Background and Objectives: Sudden cardiac death (SCD) is one of the most common causes of death in patients with heart failure (HF). However, there are no available data on SCD in previous Korean HF registries. Additionally, although widely used, the utility of left ventricular (LV) ejection fraction (EF) in risk stratification for SCD is limited.
Introduction
Sudden cardiac death (SCD) is one of the leading causes of death in the US.
1 Indeed, the annual incidence of SCD in the U.S.
was estimated from 180,000 to > 450,000 according to 6 relevant publications. [2] [3] [4] [5] Patients with heart failure (HF) are one of the wellknown, high-risk subgroups of SCD because about 50% of deaths in HF are caused by SCD, as shown in Western statistics. 6, 7 Moreover, the burden of HF is rapidly growing because of an ageing society and improvements in the management of patients with cardiovascular disease. 8 Therefore, an enhanced understanding of SCD risk factors in HF patients has become mandatory in order to improve the outcomes of HF patients.
Left ventricular (LV) ejection fraction (EF) has been the most widely used screening tool for SCD in clinical practice. However, it was previously reported that one-third of SCD cases occurred in patients with HF with preserved EF, 9 and that the proportion increased to up to two-thirds of the general population. 5 In addition, patients with EF of <30%, but without other risk factors, have a 2-year arrhythmic death risk of <5%. 10 Therefore, continued efforts to determine another risk stratification factors are necessary. T-wave alternans (TWA) and heart rate turbulence closely associated with an increased risk of SCD. [11] [12] [13] [14] However, the clinical utility of TWA and HRT has rarely been tested in Korean patients with HF.
Therefore, our objectives are to investigate the incidence and risk factors of SCD in HF patients using a newly designed, nationwide multicenter HF registry, and to evaluate the efficacy of TWA/HRT alone or in combination with other parameters for the prediction of SCD in this patient population.
Subjects and Methods

Study population
The Korean non-invasive Risk Evaluation study for sudden Patients with signs or symptoms of HF and one of the following conditions such as (i) lung congestion on a chest X-ray,
(ii) bilateral rales on physical examination, or (iii) objective findings of LV systolic dysfunction or structural heart disease will be screened for eligibility to be enrolled into the acute HF group.
Inclusion criteria for the HF group are as follows: (1) Classification of ischemic versus non-ischemic cardiomyopathy will be performed and the etiologies of non-ischemic cardiomyopathy will be determined during the index admission from among the following: valvular heart disease, congenital heart disease, cardiomyopathy, hypertensive HF, acute myocarditis, infiltrative disease, tachycardia-induced cardiomyopathy, thyroid disease-related HF, or toxic agent (chemotherapy) related HF.
Since no previous registry has specifically addressed the issue of SCD in Korean HF or MI patients, we chose to place no limitation on the sample size of the present study. Therefore, sample size was estimated based on the number of patients enrolled in previous registries of the Korean population [15] [16] [17] [18] ; 1000 consecutive patients will be enrolled for each acute HF and acute MI group, respectively, resulting in a total of 2000 patients.
Written, informed consent will be obtained from all enrolled patients. If patients are unable to give consent by themselves due to certain disabilities, obtaining an informed consent from legal representatives will be allowed. The study has been approved by the local institutional review board of each participating center. 
Study protocol and data collection
The study is funded by a grant by the Korean Heart Rhythm Society, and the study protocol and case report forms have been Table 1 .
Measurement of TWA and HRT using ambulatory ECG recording
Ambulatory electrocardiograms will be recorded during the index admission prior to discharge or within three months after discharge using an ambulatory 3-lead SEER Light Digital Holter monitor with a sampling rate of 125 samples per second (GE Healthcare Inc. Milwaukee, WI, USA). All of the participating centers will be encouraged to record Holter ECG data for at least 20 hours in order to incorporate overall circadian variation in the TWA and HRT levels during daytime and nighttime.
Additionally, a careful skin preparation will be performed to obtain a high quality signal and to minimize noise. 12 Raw ambulatory ECG data recorded at each center will be collected and sent to the core laboratory (Samsung Medical Center) to be analyzed under standardized analysis settings, the details of which in the present study are presented in Table 3 .
Discharge information and clinical outcomes during follow-up
Standardized report forms will be used to collect information at discharge and at the time of follow-up events. Discharge information will include survival status, type of death (noncardiac, non-sudden cardiac, or SCD) if occurred, type of cardiac device therapy (pacemaker, defibrillator, or biventricular pacemaker) if employed, and duration of hospitalization. Followup information will be gathered 1, 3, 6, and 12 months after discharge and annually thereafter for up to 5 years. The primary end point is SCD, which is defined as unexpected death due to cardiac causes that occurs within a short time period (within 1 hour of symptom onset or un-witnessed death during sleep).
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Other primary and secondary outcomes are shown in Table 4 . All clinical events such as death and re-hospitalization will undergo ECG, electrocardiography; HRT, heart rate turbulence; NN, normal-to-normal RR interval; TWA, T-wave alternans; VPC, ventricular premature contraction *Standard deviation of the average of NN intervals in all 5-minute segments of a 24-h recording † Percentage of differences between adjacent NN intervals that are >50 msec; this is one member of the larger pNNx family verification from an independent Clinical Event Adjudication
Committee, which consists of experts in HF and MI. The survival status and outcome data for subjects lost to follow-up will be supplemented by a telephone interview in which a structured questionnaire will be used by all participating centers.
Discussion
Burden of sudden cardiac death in Korea
SCD is among the most common causes of death in Western countries, and the rates of SCD in Korea are reportedly comparable. 19 The annual incidence of SCD in Korea was more than 41 per 100,000 people according to a recent study performed as a complete enumeration survey using the 2-year respectively. In contrast, only 6 cases per million were performed in Korea during that same year. 21 Therefore, given this situation, this registry will provide clinicians with valuable assistance in the identification of SCD 
TWA and HRT for SCD
In the K-REDEFINE study, various non-invasive parameters will be assessed prospectively such as TWA, HRT, HRV, 12-lead ECG-based data, and echocardiographic variables. TWA refers to beat-to-beat oscillation in the shape and amplitude of the ST-segment and/or T-wave. Several in vitro and in vivo experiments proved that the temporo-spatial heterogeneity of repolarization is closely associated with this phenomenon of TWA, 11 and its magnitude was well correlated with the risk of arrhythmogenesis. [22] [23] [24] Enhanced adrenergic activity and abnormal intracellular calcium handling in HF may lead to augmented inhomogeneity of repolarization, 25 which in turn may be manifested by an increased TWA level and elevated risk of lethal arrhythmia.
HRT represents a biphasic change of the sinus RR interval following ventricular premature contractions (VPCs), with an initial decrease followed by a subsequent increase. 12 The initial decrease is caused by transient vagal withdrawal following a VPCinduced reduction in blood pressure (BP), whereas the subsequent increase is related to baroreflex-mediated transient BP elevation. Therefore, HRT assessment is an indirect evaluation of baroreflex function and patients with HF frequently show blunted HRT. 12, 24, 26 TWA and HRT have already been investigated, although in most of the studies, TWA was assessed mainly in post-MI patients and merely qualitatively using the spectral method. 23, 24 Thus, the K-REDEFINE study will represent one of the largest cohorts to evaluate the association between TWA/HRT and SCD in patients with HF using ambulatory ECG data. Previous data shows contradictory results regarding abnormal HRT values in the prediction of SCD in patients with HF. 26, 27 Therefore, the K-REDEFINE study, in which TWA will be measured quantitatively using the MMA method, might promote our understanding of the role of TWA and HRT in identifying patients with HF at high risk of SCD.
Conclusion
The HF study of the K-REDEFINE registry is the first Korean prospective study primarily focused on SCD in HF patients from 25 centers in Korea. The K-REDEFINE registry will pave the way for the superior management of patients with HF who are at high risk of SCD by elucidating the burden and risk factors of SCD, as well as the clinical utility of various non-invasive ambulatory ECG-based parameters in risk stratification for SCD in this patient population.
